Product Information
TAZAROTENE 0.05% CREAM is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $8.0682 per GM under NDC 45802070696. Its NADAC has been published 85 times since Feb 19, 2025.
FDA first approved this application on Jul 15, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802070696
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
TAZAROTENEApproval Type
Generic (ANDA)
FDA Application
ANDA217075FDA Approved
7/15/2024
TE Code
AB
On Market Since
9/9/2024
Pharmacological Classes
Price Statistics
The NADAC for TAZAROTENE 0.05% CREAM has been published 85 times since Feb 19, 2025, and over the history we have for it it has declined 29.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.0682 per GM |
|---|---|
| All-time high | $11.6095 (Jun 11, 2025) |
| All-time low | $8.0046 (Aug 19, 2026) |
| 52-week high | $11.0233 |
| 52-week low | $8.0046 |
| Median price | $10.2350 |
| Average price | $10.1243 |
| Largest weekly change | -14.6% (Jun 17, 2026) |
| Weeks tracked | 85 |
| Tracking since | Feb 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the tazarotene market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tazarotene market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Retinoid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TAZAROTENE 0.05% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for TAZAROTENE 0.05% CREAM, manufactured by Padagis Israel Pharmaceuticals Ltd, is $8.0682 per GM (NDC 45802070696), effective Sep 30, 2026.
How has the price of TAZAROTENE 0.05% CREAM changed over time?
Over the history we have for it, the NADAC for TAZAROTENE 0.05% CREAM has declined 29.6%. It has been tracked across 85 weekly CMS publications since Feb 19, 2025.
What are the highest and lowest recorded NADAC prices for TAZAROTENE 0.05% CREAM?
Since Feb 19, 2025, the NADAC for TAZAROTENE 0.05% CREAM has ranged from a low of $8.0046 (Aug 19, 2026) to a high of $11.6095 (Jun 11, 2025), with a median of $10.2350 per GM.
Are there cheaper alternatives to TAZAROTENE 0.05% CREAM?
No other NADAC-published product currently shares the active ingredient and strength of TAZAROTENE 0.05% CREAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TAZAROTENE 0.05% CREAM?
TAZAROTENE 0.05% CREAM (NDC 45802070696) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.